Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV

BACKGROUND: Central nervous system (CNS) symptoms after efavirenz (EFV) treatment in people living with human immunodeficiency virus (HIV) could persist and impact their quality of life. We assessed the impact of EFV-based regimen replacement with elvitegravir/cobicistat/emtricitabine/tenofovir alaf...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Huan, Huang, Xiao-Jie, Hu, Yue, Gao, Li-Ying, Wu, Yue, Wu, Hao, Yan, Zhong-Fang, Ma, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667980/
https://www.ncbi.nlm.nih.gov/pubmed/34653085
http://dx.doi.org/10.1097/CM9.0000000000001824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667980/
https://www.ncbi.nlm.nih.gov/pubmed/34653085
http://dx.doi.org/10.1097/CM9.0000000000001824

Ejemplares similares